Mühlhauser J, Jones M, Yamada I, Cirielli C, Lemarchand P, Gloe T R, Bewig B, Signoretti S, Crystal R G, Capogrossi M C
Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Gene Ther. 1996 Feb;3(2):145-53.
Gene transfer with replication-deficient recombinant adenovirus (Ad) vectors may provide a novel approach to the treatment of some cardiac disorders. The relative efficiency of intramyocardial vs intracoronary Ad vector injection in transducing myocardial cells remains to be determined. Further, Ad vectors are associated with localized inflammation, and this could be associated with clinically significant side-effects. Female minipigs underwent open chest surgery and the Ad vector AdCMV.NLS beta-gal was injected into the circumflex coronary artery (IC; 2 x 10(10) p.f.u.; n = 5) or the posterobasal wall of the left ventricle (i.m.; 5 x 10(9) p.f.u., n = 4; 2 x 10(10) p.f.u., n = 18). The minipigs were killed after 2-31 days and the hearts examined for evidence of beta-galactosidase activity. Minipigs underwent epicardial echocardiography immediately before, within 15 min following the i.m. injection of AdCMV.NLS beta-gal and again at the time of death. Blood samples for white blood cell count, alkaline phosphatase, total bilirubin, blood urea nitrogen, creatinine and electrolytes were obtained before i.m. and i.c. injection of the Ad vector and before death. Intramuscular injection of the Ad vector was more efficient than i.c. infusion in infecting cells in a localized area of the heart. Myocardial beta-gal activity peaked at 3-6 days after i.m. injection and returned to its control value within 1 month. Although inflammatory cells were present at the injection site, echocardiograms did not show any evidence of either segmental or global left ventricular dysfunction. No minipigs died and all blood tests remained within normal limits following either i.m. or i.c. exposure to the Ad vector. In summary, direct i.m. administration of replication-deficient, recombinant Ad vectors provides a safe and effective approach for short-term gene transfer into the heart of large mammals.
使用复制缺陷型重组腺病毒(Ad)载体进行基因转移可能为某些心脏疾病的治疗提供一种新方法。心肌内注射与冠状动脉内注射Ad载体转导心肌细胞的相对效率仍有待确定。此外,Ad载体与局部炎症相关,这可能与具有临床意义的副作用有关。对雌性小型猪进行开胸手术,将Ad载体AdCMV.NLSβ-半乳糖苷酶注入左旋冠状动脉(IC;2×10¹⁰ 个感染性颗粒单位;n = 5)或左心室后基底壁(心肌内;5×10⁹ 个感染性颗粒单位,n = 4;2×10¹⁰ 个感染性颗粒单位,n = 18)。在2 - 31天后处死小型猪,并检查心脏以寻找β-半乳糖苷酶活性的证据。小型猪在心肌内注射AdCMV.NLSβ-半乳糖苷酶前、注射后15分钟内以及死亡时立即进行心外膜超声心动图检查。在心肌内和冠状动脉内注射Ad载体前以及死亡前采集血样,检测白细胞计数、碱性磷酸酶、总胆红素、血尿素氮、肌酐和电解质。在感染心脏局部区域的细胞方面,肌肉注射Ad载体比冠状动脉内输注更有效。心肌β-半乳糖苷酶活性在肌肉注射后3 - 6天达到峰值,并在1个月内恢复到对照值。尽管在注射部位存在炎性细胞,但超声心动图未显示任何节段性或整体左心室功能障碍的证据。无论是肌肉内还是冠状动脉内接触Ad载体后,均无小型猪死亡,所有血液检测结果均保持在正常范围内。总之,直接心肌内给予复制缺陷型重组Ad载体为向大型哺乳动物心脏进行短期基因转移提供了一种安全有效的方法。